ViroGates Unveils suPARnostic® TurbiLatex with Roche Diagnostics
Tue Aug 20 2019
ViroGates has finished developing and getting regulatory approval for its suPARnostic TurbiLatex product, using turbidimetric technology.
Initially cleared for the Roche Diagnostics cobas C 111 analyzer, this is a pivotal move, as Roche dominates clinical chemistry in European hospital markets with its cobas platforms.
The launch on cobas C 111 is the first step. Next, they aim to validate it on higher-throughput instruments like the cobas c 500 and c 700 series widely used in diagnostic labs.
The suPARnostic TurbiLatex automates blood sample handling at central labs. This means medical professionals can get suPAR measurements concurrently with other diagnostic data, streamlining decision-making.
The TurbiLatex product, rooted in turbidimetry, gauges the loss of transmitted light intensity due to particles in blood samples. This technique is crucial for immunoassays and forms the basis of nearly all central lab clinical chemistry instruments in hospitals.